bluebird bio (BLUE) Q2 2024 earnings summary

Executive summary

• Achieved significant progress with three commercial gene therapy launches in the U.S., supported by a robust network of over 70 qualified treatment centers and strong patient/provider demand.

• 27 patient starts completed in 2024 across ZYNTEGLO, LYFGENIA, and SKYSONA, with 43 total since approval and over 40 additional patients scheduled for cell collection by year-end; ~85 patient starts expected in 2024.

• Underwent a major restructuring in September 2024, reducing workforce by 25% to optimize cost structure.

• Restated prior period financials due to lease accounting misstatements, resulting in increased legal and accounting costs and a material weakness in internal controls.

• Expanded manufacturing capacity at Lonza, doubling output for ZYNTEGLO and SKYSONA.

Financial highlights

• Q2 2024 revenue reached $16.1 million, up from $6.8 million in Q2 2023; six-month product revenue was $34.7 million, up from $9.1 million year-over-year.

• Net loss for Q2 2024 was $81.4 million, compared to $62.8 million in Q2 2023; six-month net loss was $151.2 million.

• Gross margin for Q2 2024 was negative $12.8 million, reflecting high cost of product revenue ($28.9 million) relative to sales.

• Cash, cash equivalents, and restricted cash totaled $193.4 million as of June 30, 2024, including $49.2 million in restricted cash.

• Accumulated deficit reached $4.4 billion as of June 30, 2024.

Outlook and guidance

• On track for approximately 85 patient starts across the portfolio in 2024, with acceleration expected in the second half of the year.

• Revenue recognition expected to lag cell collection by about two quarters due to manufacturing and scheduling timelines.

• Cash runway projected into Q2 2025, or Q1 2025 when factoring in loan covenants; management acknowledges substantial doubt about ability to continue as a going concern without new funding.

• Plans to seek additional financing and implement further cost controls.

• Gross-to-net discounts expected in the 20%-25% range for all three products, reflecting payer mix and outcomes-based agreements.